Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | PPARD | Q03181 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29415497 | 1.00 | ALDH1A1 (0.55) | ALDH1A1PPARGPPARDPPARACYP3A4 | |
| SCHEMBL27002108 | 0.86 | TAAR1 (0.55) | ALDH1A1PPARGPPARDPPARACYP3A4 | |
| SCHEMBL28822968 | 0.84 | HTR2A (0.56) | ALDH1A1PPARGPPARDPPARACYP3A4 | |
| SCHEMBL12740585 | 0.84 | HTR2A (0.53) | ALDH1A1PPARGPPARDPPARACYP3A4 | |
| SCHEMBL26064966 | 0.84 | HMGCR (0.50) | ALDH1A1PPARGPPARDPPARACYP3A4 | |
| SCHEMBL3486415 | 0.84 | ALDH1A1 (0.57) | ALDH1A1PPARGPPARDPPARACYP3A4 | |
| SCHEMBL11556493 | 0.83 | ALDH1A1 (0.52) | ALDH1A1PPARGPPARDPPARACYP3A4 | |
| SCHEMBL24162733 | 0.83 | TAAR1 (0.62) | HTR2A | |
| SCHEMBL26065277 | 0.83 | HTR2A (0.49) | CYP3A4ALOX15ALOX5GABRA1GABRB2 | |
| SCHEMBL21358110 | 0.82 | GABRA1 (0.46) | ALDH1A1PPARGPPARDPPARACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118924710-A | Use of asarone in preparing medicine for treating and/or preventing eye diseases, composition and use thereof | 四川大学 | 2024-11-12 | — | — | CN | claimed |
| CN-118275560-A | Content determination and volatile oil fingerprint construction method for beta-asarone in grassleaf sweelflag rhizome | 天津中医药大学 | 2024-07-02 | — | — | CN | claimed |
| CN-114231049-A | High-strength halogen-free flame-retardant TPE cable material and preparation method thereof | 中广核高新核材集团（东莞）祈富新材料有限公司 | 2022-03-25 | — | — | CN | claimed |
| EP-1993580-A1 | COMBINATION THERAPY FOR TREATMENT OF PATIENTS WITH NEUROLOGICAL DISORDERS AND CEREBRAL INFARCTION | Moleac Pte Ltd. (SG) | 2008-11-26 | — | — | EP | claimed |
| EP-1487770-B1 | FORMATION OF NEOLIGNAN BY DDQ MEDIATED DIMERISATION OF DIHYDROASARONE | COUNCIL SCIENT IND RES (IN) | 2007-12-12 | — | — | EP | claimed |
| WO-2007106049-A1 | COMBINATION THERAPY FOR TREATMENT OF PATIENTS WITH NEUROLOGICAL DISORDERS AND CEREBRAL INFARCTION | MOLEAC PTE LTD (SG) | 2007-09-20 | — | — | WO | claimed |
| US-6969778-B2 | DDQ mediated one step dimerization of β-asarone or β-asarone rich Acorus calamus oil in the formation of novel neolignan | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2005-11-29 | — | — | US | claimed |
| EP-1487770-A1 | FORMATION OF NEOLIGNAN BY DDQ MEDIATED DIMERISATION OF DIHYDROASARONE | Council of Scientific and Industrial Research;an Indian Reg. body incorporated under Reg. of Societies Act (Act XXI of 1860) (IN) | 2004-12-22 | — | — | EP | claimed |
| US-20040049085-A1 | DDQ mediated one step dimerisation of beta-asarone or beta-asarone rich acorus calamus oil in the formation of novel neolignan | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2004-03-11 | — | — | US | claimed |
| WO-2003082786-A1 | A PROCESS FOR THE PREPARATION OF PHARMACOLOGICALLY ACTIVE ALPHA-ASARONE FROM TOXIC BETA-ASARONE RICH ACORUS CALAMUS OIL | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2003-10-09 | — | — | WO | claimed |
| US-20030187306-A1 | DDQ mediated one step dimerisation of beta-asarone or beta-asarone rich acorus calamus oil in the formation of novel neolignan | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2003-10-02 | — | — | US | claimed |
| WO-2003080551-A1 | FORMATION OF NEOLIGNAN BY DDQ MEDIATED DIMERISATION OF DIHYDROASARONE | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2003-10-02 | — | — | WO | claimed |
| US-6590127-B1 | Formation of alpha-asarone, isoacoramone and 2,4,5-trimethoxycinnamaldehyde in one step process via 2,3-dichloro-5,6-dicyano-1,4-benzoquinone assisted dehydrogenation/oxidation of 2,4,5-trimethoxyphenylpropane | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2003-07-08 | — | — | US | claimed |
| WO-2025256439-A1 | APPLICATION OF ASARONE IN PREPARATION OF DRUG FOR TREATING AND/OR PREVENTING OCULAR DISEASES, AND COMPOSITION AND APPLICATION THEREOF | 成都新睿志远生物医药股份有限公司 | 2025-12-18 | — | — | WO | disclosed |
| US-20250262306-A1 | Crosslinked Organogels for Drug Delivery | TIBET CHEEZHENG TIBETAN MEDICINE CO. LTD. (CN) | 2025-08-21 | — | — | US | disclosed |
| CN-120025234-A | Synthesis method of alpha-asarone | 湖南威特制药股份有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-5556820-A | REACTION PRODUCT OF MAGNESIUM, ALCOHOL AND HALOGEN, SOLID | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0606618-A2 | A polyolefinic resin and a resin composition comprising said resin | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 1994-07-20 | — | — | EP | disclosed |
| EP-0546192-A1 | PROCESS FOR PRODUCING OLEFIN POLYMER | IDEMITSU PETROCHEMICAL COMPANY LIMITED (JP) | 1993-06-16 | — | — | EP | disclosed |
| EP-0455813-A1 | FLEXIBLE POLYPROPYLENE RESIN, PROPYLENE ELASTOMER COMPOSITION, AND PRODUCTION OF OLEFIN POLYMER | IDEMITSU PETROCHEMICAL CO. LTD. (JP) | 1991-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049085-A1 | DDQ mediated one step dimerisation of beta-asarone or beta-asarone rich acorus calamus oil in the formation of novel neolignan | DHPS, PTGES, PTGIS | ALDH1A1 302/4885PPARG 1650/4885PPARD 1740/4885 |
| US-20030187306-A1 | DDQ mediated one step dimerisation of beta-asarone or beta-asarone rich acorus calamus oil in the formation of novel neolignan | DHPS, PTGES, PTGIS | ALDH1A1 302/4885PPARG 1650/4885PPARD 1740/4885 |
| US-20250262306-A1 | Crosslinked Organogels for Drug Delivery | DSG1, LIPG, DSP | ALDH1A1 1958/4885PPARG 906/4885PPARD 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.